Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

B-cell lymphoma 6 (BCL6) is a transcription repressor and proto-oncogene that plays a crucial role in the innate and adaptive immune system and lymphoid neoplasms. However, its role in myeloid malignancies remains unclear. Here, we explored the role of BCL6 in acute myeloid leukemia (AML). BCL6 was expressed at variable and often high levels in AML cell lines and primary AML samples. AMLs with higher levels of BCL6 were generally sensitive to treatment with BCL6 inhibitors, with the exception of those with monocytic differentiation. Gene expression profiling of AML cells treated with a BCL6 inhibitor revealed induction of BCL6-repressed target genes and transcriptional programs linked to DNA damage checkpoints and downregulation of stem cell genes. Ex vivo treatment of primary AML cells with BCL6 inhibitors induced apoptosis and decreased colony-forming capacity, which correlated with the levels of BCL6 expression. Importantly, inhibition or knockdown of BCL6 in primary AML cells resulted in a significant reduction of leukemia-initiating capacity in mice, suggesting ablation of leukemia repopulating cell functionality. In contrast, BCL6 knockout or inhibition did not suppress the function of normal hematopoietic stem cells. Treatment with cytarabine further induced BCL6 expression, and the levels of BCL6 induction were correlated with resistance to cytarabine. Treatment of AML patient-derived xenografts with BCL6 inhibitor plus cytarabine suggested enhanced antileukemia activity with this combination. Hence, pharmacologic inhibition of BCL6 might provide a novel therapeutic strategy for ablation of leukemia-repopulating cells and increased responsiveness to chemotherapy.

Original publication

DOI

10.1182/blood.2019001745

Type

Journal article

Journal

Blood

Publication Date

11/02/2021

Volume

137

Pages

812 - 825

Keywords

Animals, Antineoplastic Agents, Apoptosis, Cell Self Renewal, Cytarabine, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Gene Knockdown Techniques, Hematopoietic Stem Cells, Humans, Indoles, Leukemia, Myeloid, Acute, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Proteins, Neoplastic Stem Cells, Proto-Oncogene Mas, Proto-Oncogene Proteins c-bcl-6, RNA Interference, RNA, Messenger, RNA, Neoplasm, RNA, Small Interfering, RNA-Seq, Radiation Chimera, Thiazolidinediones, Tumor Stem Cell Assay, Xenograft Model Antitumor Assays